CG-100 Temporary intraluminal bypass device designed to reduce the rate of diverting stoma and its related complication by at least 70%
- Coordinator
- Colospan Ltd, Israel
- Runs
- 1 June 2022 to 31 May 2025
- Status
- Running
- EU funding
- €2.3m
- Total cost
- €3.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190124297
What the project is doing
In the project's own words, from its summary on CORDIS.
Anastomotic leakage of colon content into the abdominal cavity is the most devastating complication associated with colorectal surgery. Leaks occur in ~22% of cases, leading to increased hospitalization time, higher re-operation rates, increased patient mortality & additional costs. To minimize the risk of a leak, surgeons create a loop of the small bowel which is diverted outside the abdominal wall & connected to a stoma bag to collect patients feces for 4-6 months.
Diverting stoma significantly diminishes patients quality of life, increases cost of care & requires an additional invasive surgery to reverse the stoma. Our novel device, CG-100, is an elastic tubular sheath that is positioned at the anastomosis site during the primary colorectal surgery & creates an internal bypass for all colon content. CG-100 is removed non-surgically 10 days after primary surgery. CG-100 addresses will improve patient quality of life, save ~1350 pa lives & reduce healthcare costs by 4B pa in EU.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Colospan Ltd | Kfar Saba | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI